Abstract
AbstractAfter the first successful clinical trials of monometallic photosensitizers (PSs) for photodynamic therapy (PDT), the use of polynuclear complexes is currently coming to the fore. These increasingly complex systems bear a high potential to overcome the drawbacks of their mononucleic peers by, for example, increasing the solubility of the PDT PSs and therefore their pharmacokinetic behavior, changing their internal quantum, and singlet oxygen efficiencies or adding supplementary imaging or therapeutical modalities, thus opening up the field for approaches in personalized medicine by combining therapy and diagnosis together in a single treatment. In this review, the most promising examples of polymetallic complexes used as PSs for anticancer PDT are presented.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
